Standout Papers

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial 2024 202653
  1. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial (2024)
    Kang Wang, Yan‐Jun Xiang et al. Nature Medicine

Citation Impact

9 standout
Sub-graph 1 of 4

Citing Papers

EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment
2024 Standout
1 intermediate paper

Works of Yan‐Jun Xiang being referenced

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Transcatheter Arterial Chemoembolization Plus Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma: a Single-Arm, Phase II Trial
2022

Author Peers

Author Hepatology Surgery PFM Oncology Epidemiology Last Decade Papers Cites
Yan‐Jun Xiang 204 48 65 73 73 28 259
Jiachun Ge 4 1 1 38 514
Анна А. Штро 4 7 10 21 187 62 934
Antje Winkler 4 129
Geri Kreitzer 22 140 44 129 110 35 2.4k
R. Rabe 1 8 341

All Works

Loading papers...

Rankless by CCL
2026